GSE113486 ( miRNA )

Hepatocellular Carcinoma ( liver )

Circulating miRNA panels for specific and early detection in bladder cancer

Cancer : 40 / Control : 100

The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetected) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.

A serum miRNA combination could be a powerful classifier for the detection of patients with bladder cancer.

Serum microRNA profiles of 972 samples, which consist of 392 bladder cancer, 100 non-cancer control, and 480 other types of cancer patients.

Usuba W, Urabe F, Yamamoto Y, Matsuzaki J et al. Circulating miRNA panels for specific and early detection in bladder cancer. Cancer Sci 2019 Jan;110(1):408-419. PMID: 30382619

Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).

total RNA

Cy5

miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.

Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol were attached in the 3D-Gene® miRNA oligo chip kit.

3D-Gene Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).